Edesa Biotech, Inc. - Common Shares – Jahresabschlüsse (NASDAQ:EDSA) | MetaTrader

Vollständige Grafik anzeigen Full chart

Nachrichten

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.95%

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.83%

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.76%

Edesa-Biotech-Aktie schießt nach positiven Phase-3-Studiendaten in die Höhe

Edesa Biotech stock surges on positive Phase 3 trial data

Edesa Biotech reports mortality reduction in phase 3 trial

Edesa Biotech erweitert "At-the-Market"-Angebot auf 2,26 Millionen US-Dollar/n

Edesa Biotech increases at-the-market offering limit to $2.26 million

Edesa Biotech, Inc. (EDSA) Presents at LSX Investival Showcase Europe 2025 - Slideshow (NASDAQ:EDSA) 2025-11-17

Edesa Biotech meldet signifikanten Erfolg in Phase-3-Studie zu ARDS-Medikament

Edesa Biotech reports positive Phase 3 results for ARDS drug candidate

Edesa’s ARDS drug shows 25% reduction in death risk in phase 3 trial